Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin

University of Nebraska

Status: Completed

Conditions: Cardiac Toxicity; Chemotherapeutic Agent Toxicity; Lymphoma

Treatments: Procedure: contrast-enhanced magnetic resonance imaging

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT00577798

UNMC-40907

P30CA036727 (U.S. NIH Grant/Contract)

0409-07-FB

Details and patient eligibility

About

RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.

PURPOSE: This clinical trial is studying how well cardiac magnetic resonance imaging works in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin.

Full description

OBJECTIVES:

• To determine whether early myocardial structural and functional changes can be detected using cardiac MRI in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin hydrochloride-based chemotherapy.

OUTLINE: Patients undergo cardiac MRI with gadolinium contrast prior to initiation of doxorubicin hydrochloride-based chemotherapy and 3 months after completion of six courses of chemotherapy for non-Hodgkin lymphoma and twelve courses of chemotherapy for Hodgkin lymphoma.

Enrollment: 10 patients

Sex: All

Ages: 19 to 120 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Diagnosis of non-Hodgkin lymphoma or Hodgkin lymphoma

  o Newly diagnosed disease

• Planning to receive doxorubicin hydrochloride-based chemotherapy solely at the University of Nebraska Medical Center

• Fertile patients must use effective contraception

• Able to lie flat for 90 minutes

• Able to fulfill the requirements of the study

Exclusion criteria

• Not pregnant or nursing
• No pacemaker
• No chronic kidney disease stages 3-5 (glomerular filtration rate < 60 mL/min)
• No metallic foreign body not approved for MRI
• No known hypersensitivity to gadolinium contrast or other required drugs in the study
• No comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this study
• No prior chemotherapy
• No prior radiotherapy to mantle or mediastinum

Trial design

10 participants in 1 patient group

Observational

Description:

Only had observational arm

Treatment:

Procedure: contrast-enhanced magnetic resonance imaging